Evidence for peri-lacunar remodeling and altered osteocyte lacuno-canalicular network in mouse models of myeloma-induced bone disease.

bone lacuno-canalicular network myeloma osteocytes peri-lacunar remodeling synchrotron

Journal

JBMR plus
ISSN: 2473-4039
Titre abrégé: JBMR Plus
Pays: England
ID NLM: 101707013

Informations de publication

Date de publication:
Sep 2024
Historique:
received: 22 03 2024
revised: 11 06 2024
accepted: 10 07 2024
medline: 7 8 2024
pubmed: 7 8 2024
entrez: 7 8 2024
Statut: epublish

Résumé

Myeloma bone disease (MBD) affects ~90% of multiple myeloma patients, but current treatment options are suboptimal. Therefore, to successfully develop new therapies or optimize current ones, we must improve our fundamental knowledge of how myeloma affects bone microstructure and function. Here, we have investigated the osteocyte lacuno-canalicular network (LCN) in MBD, as bone porosity affects bone quality and resilience. We used the syngeneic 5TGM1-C57BL-Kalwrij and the xenograft U266-NSG models at end stage and compared them to healthy controls (naïve). Micro-computed tomography (μCT) and histomorphometry indicated the 5TGM1 and U266 models developed mild and extensive MBD, respectively, with the U266 model producing large osteolytic lesions. High-resolution synchrotron micro-CT (SR-μCT) revealed significant osteocyte lacunae changes in U266 bones but not 5TGM1, with a reduction in lacunae number and sphericity, and an increase in lacunae volume compared with naïve. Canalicular length, visualized using histological Ploton silver staining, appeared significantly shorter in 5TGM1 and U266 bones compared with naïve. Canalicular area as a proportion of the bone was also decreased by 24.2% in the U266 model. We observed significant upregulation of genes implicated in peri-lacunar remodeling (PLR), but immunohistochemistry confirmed that the osteocyte-specific protein sclerostin, a known driver of PLR, was unchanged between MBD and naïve bones. In summary, we have demonstrated evidence of PLR and altered organization of the osteocyte LCN in MBD mouse models. The next step would be to further understand the drivers and implications of PLR in MBD, and whether treatments to manipulate PLR and the LCN may improve patient outcomes.

Identifiants

pubmed: 39108360
doi: 10.1093/jbmrpl/ziae093
pii: ziae093
pmc: PMC11299509
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ziae093

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.

Déclaration de conflit d'intérêts

The authors have no conflicts to report.

Auteurs

Holly Evans (H)

Division of Clinical Medicine and Mellanby Centre for Musculoskeletal Research, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield S10 2RX, United Kingdom.

Rebecca Andrews (R)

Division of Clinical Medicine and Mellanby Centre for Musculoskeletal Research, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield S10 2RX, United Kingdom.
Department of Haematology, Sheffield Teaching Hospitals, Royal Hallamshire Hospital NHS Foundation Trust, Sheffield S10 2JF, United Kingdom.

Fatma Ali Abedi (FA)

Division of Clinical Medicine and Mellanby Centre for Musculoskeletal Research, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield S10 2RX, United Kingdom.

Alexandria Sprules (A)

Division of Clinical Medicine and Mellanby Centre for Musculoskeletal Research, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield S10 2RX, United Kingdom.

Jacob Trend (J)

School of Biological Sciences, University of Southampton, Southampton SO17 1BJ, United Kingdom.

Goran Lovric (G)

TOMCAT beamline, Swiss Light Source, Paul Scherrer Institut, Forschungsstrasse 111, 5232 Villigen, Switzerland.

Alanna Green (A)

Division of Clinical Medicine and Mellanby Centre for Musculoskeletal Research, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield S10 2RX, United Kingdom.

Andrew Chantry (A)

Division of Clinical Medicine and Mellanby Centre for Musculoskeletal Research, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield S10 2RX, United Kingdom.
Department of Haematology, Sheffield Teaching Hospitals, Royal Hallamshire Hospital NHS Foundation Trust, Sheffield S10 2JF, United Kingdom.

Claire Clarkin (C)

School of Biological Sciences, University of Southampton, Southampton SO17 1BJ, United Kingdom.

Janet Brown (J)

Division of Clinical Medicine and Mellanby Centre for Musculoskeletal Research, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield S10 2RX, United Kingdom.
Department of Haematology, Sheffield Teaching Hospitals, Royal Hallamshire Hospital NHS Foundation Trust, Sheffield S10 2JF, United Kingdom.

Michelle Lawson (M)

Division of Clinical Medicine and Mellanby Centre for Musculoskeletal Research, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield S10 2RX, United Kingdom.

Classifications MeSH